Georgia Medical Society Opposes Cannabis Expansion Bill

Physician Group Targeted Condition Expansion

The Medical Association of Georgia testified against HB 324, which would've expanded qualifying conditions to include chronic pain, PTSD, and opioid use disorder. The group argued in written testimony submitted May 26 that the additions lacked sufficient clinical evidence. They said the changes could undermine Georgia's restrictive approach to medical cannabis.

Georgia currently allows low-THC oil (less than 5% THC) for 16 qualifying conditions including cancer, seizure disorders, and Crohn's disease. The state doesn't permit cultivation or retail dispensaries. Patients must purchase oil from out-of-state sources or in-state manufacturers operating under a 2019 production license framework.

Bill Stalled in Senate Committee

HB 324 passed the Georgia House 98-67 in March but died in the Senate Regulated Industries Committee on May 22 without a floor vote. The Medical Association's testimony arrived four days before the committee's final session. Legislative records show the physician group registered opposition alongside the Georgia Sheriffs' Association and the Prosecuting Attorneys' Council.

Rep. Micah Gravley (R-Douglasville) sponsored the bill. He said in floor remarks that the measure was designed to help veterans with PTSD and pain patients facing opioid restrictions. For full background on this story, see the CannIntel topic hub on Georgia Cannabis Legislation.

What Happens Next

The 2026 legislative session ended May 23, meaning any expansion effort must restart in the 2027 session beginning January. Advocates say they'll reintroduce similar language next year. Georgia remains one of 14 states with a medical cannabis program that prohibits in-state retail sales and limits THC content below typical therapeutic thresholds.

The next legislative window opens in January 2027. Watch for condition-expansion bills in the first weeks of session.